Clinical trials: Esophageal Sensitivity
Sensitivity in Esophagus
Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.
- Trial name
- NCT01019928
- Testing
- AZD1386
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Eosinophilic Esophagitis
Cytosponge and Dietary Therapy in EoE
This study is being done to see if the investigators can use only the cytosponge ( A 10 minute, in office procedure that does not require sedation) to replace the 6-10 endoscopies routinely perform during dietary restriction and…
- Trial name
- NCT02599558
- Testing
- Cytosponge
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis
Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis
This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.
- Trial name
- NCT00638456
- Testing
- Budesonide plus Prevacid
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ranjan Dohil
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
- Trial name
- EoDyssey (NCT04856891)
- Testing
- AK002
- Where
- 39 sites in United States
- Volunteers
- 94 people
- Sponsor
- Allakos Inc.